



# Systematic Review Nasal Cannula with Long and Narrow Tubing for Non-Invasive Respiratory Support in Preterm Neonates: A Systematic Review and Meta-Analysis

Pratima Anand <sup>1</sup>, Monika Kaushal <sup>2</sup>, Viraraghavan Vadakkencherry Ramaswamy <sup>3</sup>, Abdul Kareem Pullattayil S. <sup>4</sup>, Abdul Razak <sup>5,6</sup> and Daniele Trevisanuto <sup>7,\*</sup>

- <sup>1</sup> Division of Neonatology, Department of Paediatrics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi 110029, India
- <sup>2</sup> Department of Neonatology, Emirates Speciality Hospital, Dubai P.O. Box 505240, United Arab Emirates
- <sup>3</sup> Department of Neonatology, Ankura Hospital for Women and Children, Hyderabad 520072, India
- <sup>4</sup> Health Sciences Library, Queen's University, Kingston, ON K7L 3N6, Canada
- <sup>5</sup> Division of Neonatology, Department of Paediatrics, Princess Nourah Bint Abdulrahman University,
- King Abdullah Bin Abdulaziz University Hospital, Riyadh 11564, Saudi Arabia
- <sup>6</sup> Department of Paediatrics, Monash University, Clayton, VIC 3800, Australia
- <sup>7</sup> Department of Woman and Child Health, University of Padua, University Hospital of Padua, 35128 Padua, Italy
- Correspondence: daniele.trevisanuto@unipd.it; Tel.: +39-34066327341

Abstract: Background: Cannulas with long and narrow tubing (CLNT) are increasingly being used as an interface for noninvasive respiratory support (NRS) in preterm neonates; however, their efficacy compared to commonly used nasal interfaces such as short binasal prongs (SBP) and nasal masks (NM) has not been widely studied. Material and Methods: Medline, Embase, CENTRAL, Health Technology Assessment Database, and Web of Science were searched for randomized clinical trials (RCTs) and observational studies investigating the efficacy of CLNT compared to SBP or NM in preterm neonates requiring NRS for primary respiratory and post-extubation support. A randomeffects meta-analysis was used for data synthesis. Results: Three RCTs and three observational studies were included. Clinical benefit or harm could not be ruled out for the outcome of need for invasive mechanical ventilation (IMV) for CLNT versus SBP or NM [relative risk (RR) 1.37, 95% confidence interval (CI) 0.61–3.04, certainty of evidence (CoE) low]. The results were also inconclusive for the outcome of treatment failure [RR 1.20, 95% CI 0.48-3.01, CoE very low]. Oropharyngeal pressure transmission was possibly lower with CLNT compared to other interfaces [MD -1.84 cm H20, 95% CI -3.12 to -0.56, CoE very low]. Clinical benefit or harm could not be excluded with CLNT compared to SBP or NM for the outcomes of duration of IMV, nasal trauma, receipt of surfactant, air leak, and NRS duration. Conclusion: Very low to low CoE and statistically nonsignificant results for the clinical outcomes precluded us from making any reasonable conclusions; however, the use of CLNT as an NRS interface, compared to SBP or NM, possibly transmits lower oropharyngeal pressures. We suggest adequately powered multicentric RCTs to evaluate the efficacy of CLNT when compared to other interfaces.

**Keywords:** nasal cannula; neonate; noninvasive respiratory support; preterm infant; respiratory distress; systematic review

# 1. Introduction

Respiratory distress is a common occurrence in the neonatal period which warrants intensive care admission, and an appropriate strategy for respiratory support is critical to improve neonatal outcomes. There is widespread use of noninvasive respiratory support (NRS) including high-flow nasal cannula (HFNC), nasal continuous positive airway pressure (nCPAP), biphasic CPAP (BiPAP), nasal intermittent positive pressure



Citation: Anand, P.; Kaushal, M.; Ramaswamy, V.V.; Pullattayil S., A.K.; Razak, A.; Trevisanuto, D. Nasal Cannula with Long and Narrow Tubing for Non-Invasive Respiratory Support in Preterm Neonates: A Systematic Review and Meta-Analysis. *Children* **2022**, *9*, 1461. https://doi.org/10.3390/ children9101461

Academic Editor: Carlo Dani

Received: 31 August 2022 Accepted: 20 September 2022 Published: 23 September 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). ventilation (NIPPV), synchronized NIPPV, nasal high-frequency ventilation (nHFOV), and non-invasive neurally adjusted ventilatory (NIV NAVA), all of which may be used as a primary modality for respiratory support or for post-extubation in respiratory distress in neonates [1,2]. Amongst the various NRS modalities, NIPPV have been shown to be probably the most efficacious modality for preventing the need for invasive mechanical ventilation or treatment failure when used as a primary or post-extubation support [1,3].

Apart from the type of NRS, nasal interfaces for applying NRS also play an important role in preventing treatment failure. The resistance to flow and pressure transmission, and hence the clinical outcomes, may be influenced by the choice of interface [4]. It is also important to note that the force applied on the nasal skin does not compromise the skin integrity and result in nasal trauma [5–11]. In addition, the perceived comfort of the neonate and the ease of use for the health personnel are the other important factors that determine the choice of interface in many neonatal care units [3].

Short binasal prongs (SBP) [Hudson (Hudson RCI, Temecula, CA, USA), Fisher & Paykel (Fischer & Paykel Healthcare, Auckland, New Zealand) & Argyll (Cardinal Health, Dublin, OH, USA)], nasal masks (NM), and nasopharyngeal tubes are the common interfaces utilized for instituting NRS [12]. These interfaces have been studied for clinical efficacy over the last decade, with a recent meta-analysis indicating NM to be more effective when compared to SBP in preventing endotracheal intubation within 72 h of initiating nCPAP [13]. This meta-analysis also reported a reduced risk of nasal trauma with NM compared to SBP while delivering nCPAP support in preterm neonates.

RAM Cannula (Neotech, Valencia, NM, USA), a type of cannula with long and narrow tubing (CLNT), has been approved by the Food and Drugs Administration (FDA) as a class-1 medical device for providing supplemental oxygen with 60% to 80% occlusion of the nares [14]. It is used off-label in many NICUs as an interface for nCPAP and NIPPV, as it is perceived to be associated with less discomfort and nasal trauma [12,14,15]. Simulationbased lung studies on pressure transmission and tidal volume generation using CLNT have reported equivocal results [16–20]. Some of the studies have shown that resistance to air flow is higher with CLNT than with SBP [18]. There is a lot of ambiguity in the published literature with respect to pressure transmission with CLNT [19,21]. Similarly, results from clinical studies on CLNT in preterm neonates show conflicting data on various outcomes such as treatment failure and need for invasive mechanical ventilation (IMV) [21-26]. It is therefore essential that the literature related to CLNT is systematically evaluated to derive meaningful conclusions about its use in clinical practice. This meta-analysis is hence aimed to study the effect of any NRS given with CLNT, otherwise referred to as RAM cannula, compared with SBP, NM, or both on the various outcomes in preterm neonates requiring NRS for initial treatment or for post-extubation.

#### 2. Materials and Methods

The protocol was registered with PROSPERO (CRD42021226178 available at https: //www.crd.york.ac.uk/prospero/ accessed on 1 September 2022), and the reporting of this systematic review is in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) framework [27].

#### 2.1. Literature Search

The following electronic databases were searched from the inception until 7 July 2022: Medline, Embase, The Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Methodology Register), the Health Technology Assessment Database, and the Web of Science. There were no language restrictions. Two authors (M.K. and P.A.) performed the literature search independently. References in the included studies and trial registries such as World Health Organization (WHO) and ClinicalTrials.gov were also searched. Conference abstracts of pediatric academic societies from the last three years were searched and were included only if sufficient data was available for risk-of-bias assessment. Lastly, citations of the included

studies were also searched for possible inclusion. The literature search strategy for all the databases is provided in Supplement Table S1.

#### 2.2. Inclusion Criteria

Randomized controlled trials (RCTs), quasi-RCTs, crossover trials, and observational studies were eligible for inclusion. Descriptive studies with no control arm, narrative reviews, case reports, case series, commentaries, and letters to editors were excluded.

Population: Preterm neonates (<37 weeks' gestation) requiring NRS modalities of NIPPV or NCPAP as primary or post-extubation support were included.

# Intervention: CLNT Comparators: SBP or NM

#### 2.3. Outcomes

#### 2.3.1. Primary Outcome

Treatment failure was defined as the need for escalation to a higher mode of NRS or the need for invasive mechanical ventilation (IMV) at any time within the first 7 days of initiating the support. The indication and criteria for escalation of respiratory support was as defined by the study authors. As treatment failure and the need for IMV are not mutually exclusive, we considered treatment failure and the need for IMV separately as primary outcomes.

#### 2.3.2. Secondary Outcomes

- i. Clinical outcomes: receipt of surfactant therapy, air leak (as defined by authors), nasal trauma occurring at any time until the discontinuation of respiratory support (any grade and severity, as defined by the authors), and duration of IMV and NRS (days).
- ii. Surrogate outcomes: pressure transmission at the level of the pharynx or esophagus and the work of breathing (using an objective and validated scoring technique).

#### 2.4. Data Extraction, Data Synthesis, and Quality of Evidence

Data extraction was performed by two authors independently using a prespecified structured proforma. R-software (version 3.6.2) (R Foundation for Statistical Computing, Vienna, Austria) was used for the meta-analysis [28]. The Mantel–Haenszel method and the inverse variance method for dichotomous outcomes and continuous outcomes were utilized, respectively. Between the studies, heterogeneity was evaluated using Cochran Q, I2, and  $\tau 2$  values. The random-effects model was preferred over the fixed-effects model; this was owing to the fact that clinical heterogeneity was anticipated between the studies, as some of the studies had enrolled neonates in whom NRS was used as a primary modality, while others used a mixture of primary as well as post-extubation modality. Also, the type of respiratory support varied, with some utilizing CPAP and others NIPPV.

The overall effect estimate for each of the outcomes was expressed as risk ratios (RR) and risk difference (RD) for dichotomous outcomes and mean differences (MD) for continuous outcomes, with their 95% confidence interval (CI) depicted using forest plots. The within-group standard error of the mean (SEM) reported in a trial was converted to the corresponding standard deviation (SD) [29]. Publication bias was planned to be assessed by using funnel plots if we included 10 or more clinical trials in the meta-analysis.

#### 2.5. Risk-of-Bias (RoB) Assessment

Cochrane RoB tool version 2.0 was utilized for RCTs [30] and Risk of Bias in Nonrandomized Studies of intervention (ROBINS-I) for non-RCTs [31]. Two authors (V.R. and A.R.) assessed the RoB independently, and conflicts were resolved by consensus and discussion.

## 2.6. Certainty of Evidence (CoE) Assessment

Grading of recommendations, assessment, development, and evaluations (GRADE) was used for assessing the CoE, which was rated as high, moderate, low, or very low [32–34]. The results of the meta-analysis were reported as per a modified GRADE working group recommendation [35] (Supplement Table S2).

#### 2.7. Subgroup Analysis

The studies were pooled as subgroups depending on the type of NRS and the indication for NRS for investigating the heterogeneity:

- i. type of NRS: NCPAP vs. NIPPV
- ii. indication for NRS: primary, post-extubation, or both

We intended to pool the results based on the gestational age of the neonates: <28 weeks and  $\geq$ 28 weeks if two or more studies provided separate data for the relevant subgroup.

# 3. Results

Of the 105 studies identified during the systematic search of the literature, a total of six studies were included (RCTs: 3 studies (Maram 2021, Hochwald 2021, and Gokce 2021) (n = 521); [24–26] observational studies: 3 studies (Singh 2018, Sharma 2020, Drescher 2018) (n = 138)) [21,23]. The PRISMA flow is depicted in Figure 1. The three RCTs had enrolled neonates born at a gestational age of 28–34 weeks [24–26]. Two of the RCTs (Gokce 2021 and Hochwald 2021) [24,25] used NIPPV as the NRS modality, and one (Maram 2021) used CPAP [26]. Two of the RCTs (Maram 2021 and Gokce 2021) [24,26] included enrolled neonates who were instituted NRS as primary respiratory support, and one (Hochwald 2021) used it both as primary and as post-extubation [25]. The characteristics of the included studies are given in Table 1. The reasons for the studies that were excluded are given in Supplement Table S3 [4,17,19,21,36–39]. The comparator in four of the six included studies was SBP [18,23–26]. In the remainder of the studies, multiple interfaces were used, including SBP [22,25].

Table 1. Characteristics of the included studies.

Study ID, Year, Country	Intervention	Comparator	GA (Weeks) Mean ± SD or Median (IQR)	BW (g) Mean ± SD or Median (IQR)	Type of NRS Used	Study Outcomes	Other Comments
Maram et al. 2021 India [26]	CPAPwith RAM cannulae with can- nulaide	CPAP with short binasal prongs	I: 31.4 ± 1.7 C:31.4 ± 1.6	I: 1491 ± 321 C: 1531 ± 394	CPAP as primary respiratory support	Primary outcome: Incidence and severity of nasal injury Secondary outcomes: Nasal injury score at discharge Need for IMV Duration of nasal CPAP Need for change in interface Mortality CPAP failure Culture positive sepsis PDA NEC IVH grade 3 or more Cystic PVL ROP needing laser Supplemental oxygen at 28 days Air leak Transfer to other hospital Discharge from hospital Length of hospital stay Weight at discharge Head circumference at discharge	Inclusion criteria: Neonates between 28 to 34 weeks of gestation, stratified based on GA 28 to 30 weeks and 31 to 34 weeks Exclusion criteria: Neonates who required IMV at admission to NICU; those with poor respiratory efforts or apnea, worsening shock, suspected or proven persistent pulmonary hypertension of newborn, severe metabolic acidosis (pH < 7.20 and base deficit > 10), severe respiratory acidosis (pH < 7.20 and PaCO2 > 60 mm Hg), and massive pulmonary haemorrhage. Neonates with major congenital malformations such as congenital diaphragmatic hernia, tracheo-oesophageal fistula, Pierre Robin sequence, and choanal atresia were excluded.

Study ID,

Study Outcomes	Other Comments
Primary outcome:	
Need for IMV (failure of	
NIPPV) within the first 72 h of	
life	Inclusion criteria: Neonates
Need for surfactant	between 26 to 33 <sup>+6</sup> weeks
Secondary outcomes:	gestation stratified from
Duration of NIPPV	26 weeks to 29 <sup>+6</sup> weeks and 30
Duration of IMV	to 33 <sup>+6</sup> weeks
Duration of supplemental	Exclusion criteria: Infants who
oxygen	required intubation in the

Study ID, Year, Country	Intervention	Comparator	Mean ± SD or Median (IQR)	Mean ± SD or Median (IQR)	Type of NRS Used	Study Outcomes	Other Comments
Gokce et al. 2019 Turkey [24]	NIPPV(non- synchronised) using RAM cannula	NIPPV using short binasal prongs	All: 29.6 $\pm$ 2.0 I: 29.5 $\pm$ 2.2 C: 29.8 $\pm$ 1.8	All: $1254 \pm 348$ I: $1255 \pm 348$ C: $1253 \pm 350$	Non syn- chronised NIPPV as primary support	Primary outcome: Need for IMV (failure of NIPPV) within the first 72 h of life Need for surfactant Secondary outcomes: Duration of NIPPV Duration of IMV Duration of supplemental oxygen Incidence of nasal injury: nasal septal injury stage 1 or 2 NEC IVH > grade 2 Pneumothorax Pulmonary interstitial emphysema Pulmonary haemorrhage BPD Duration of hospital stay Death	Inclusion criteria: Neonates between 26 to 33 <sup>+6</sup> weeks gestation stratified from 26 weeks to 29 <sup>+6</sup> weeks and 30 to 33 <sup>+6</sup> weeks Exclusion criteria: Infants who required intubation in the delivery room, those with a major congenital anomaly, or those were transferred to hospital after birth in another center.
Hochwald et al. 2021 Israel [25]	Synchronised NIPPV using RAM cannula	NIPPV with short binasal prongs	I: 29.3 ± 2.2 C: 29.2 ±2.5	I: 1237 ± 414 C: 1254 ±448	Synchronised NIPPV (Primary respiratory support and post extubation)	Primary outcome: Treatment failure within 72 h after initiation of NIPPV, i.e., need for IMV	Inclusion criteria: Neonates between 24 to 33 <sup>+6</sup> weeks gestation Exclusion criteria: Infants with significant morbidity apart from RDS, including cardiac disease (not including patent ductus arteriosus), congenital malformation, or if they had cardiovascular or respiratory instability because of sepsis, anaemia, or severe IVH.
Singh et al. 2021 U.S.A [23]	CPAP using RAM cannula	CPAP using short binasal prongs	$28.1\pm2.1$	$1225\pm405$	СРАР	Intraoral (pharyngeal) pressures	Inclusion criteria: Any preterm infant with respiratory distress requiring CPAP but not IMV or NIPPV Exclusion criteria: Critically ill or had major congenital anomalies, neuromuscular disorders, or upper airway anomalies.
Sharma et al. 2020 India [18]	CPAP using RAM cannula	CPAP using nasal mask or short binasal prongs	I: 32 (29 to 33) C: 32(29 to 33)	I: 1331 ± 228 C: 1382 ± 209	СРАР	Mean pharyngeal pressure	Inclusion criteria: Preterm neonates with gestation 28 to 34 weeks and BW more than or equal to 1000 g and requiring nasal CPAP for respiratory distress. Exclusion criteria: infants who were critically ill and those who had major congenital anomalies or upper airway malformations.
Drescher et al. 2018 USA [22]	NRS which included CPAP, NIPPV and HH- HFNC using RAM cannula (with barrier nursing).	NRS using all other interfaces before the implementa- tion of RAM system as interface in 2014. (Historical control).	I: $26.9 \pm 1.3$ C: $26.4 \pm 1.6$	I: 879 ±192.9 C: 866.6 ± 185.4	NIPPV (Primary respiratory support and post extubation)	Total IMV courses Total IMV duration Initial IMV duration Successful extubation Time until initial re-intubation Total re-intubations NRS failure < 7 days Total duration of CPAP Total duration of NIPPV Total duration of NIPPV Total duration of HFNC Total duration of nasal cannula use Total duration of NRS Total duration of respiratory support BPD Skin and/or mucosal breakdown	Inclusion criteria: Neonates < 1500 g and/or less than 29 weeks, gestation Exclusion criteria: any infant who died before the initiation of NRS or who was transferred before 36 weeks' postmenstrual age.

GA: gestational age, BW: birth weight, SD: standard deviation, IQR: interquartile range, NRS: noninvasive respiratory support, CPAP: continuous positive airway pressure, NEC: necrotising enterocolitis, PDA: patent ductus arteriosus, IVH: intraventricular hemorrhage, PVL: periventricular leukomalacia, ROP: retinopathy of prematurity, BPD: bronchopulmonary dysplasia, IMV: invasive mechanical ventilation, NIPPV: noninvasive positive pressure ventilation, HFNC: high flow nasal cannula, I: intervention, C: comparator.

Table 1. Cont.

GA (Weeks) Mean  $\pm$  SD

 $\begin{array}{c} \text{BW (g)}\\ \text{Mean}\pm\text{SD} \end{array}$ 



Figure 1. PRISMA flow.

## 3.1. RoB of the Included Studies

Of the three RCTs included, one provoked concern due to issues in the domain randomization process (Gokce 2019), and the other two RCTs (Hochwald 2021, Maram 2019) had a low risk of overall bias [24–26]. For these RCTs, the randomization process was Web-based, deviations from intended interventions were minimal, the measured outcomes were objective, there was no missing data, and all the selected outcomes were reported.

Among the non-randomized studies, two (Sharma 2020 and Drescher 2018) had a serious risk of overall bias predominantly contributed by confounding, and one had moderate risk of bias in the domain of measurement of outcomes (Singh 2018) [18,23]. The risk of bias in the included studies is given in Supplement Table S4 (randomized trials) and Supplement Table S5 (non-randomized trials).

## 3.2. Outcomes from Randomised Trials

# 3.2.1. Primary Outcomes

## Treatment Failure

Clinical benefit or harm could not be ruled out for the outcome of treatment failure between the two groups [RR 1.20, 95% CI 0.48–3.01; 3 studies, 521 participants]. The CoE was downgraded to very low certainty due to limitations in the study design, indirectness, inconsistency, and imprecision (Figure 2, Table 2). The test for subgroup differences was not significant.

Study	RAM ca Events		Events	Others Total	Treatment failure	RR	95%-CI	Weight (fixed)	Weigh (random
Primary respiratory sup	aport				18				
Maram 2021	12	112	21	117		0.60	[0.31; 1.16]	47.1%	34.1
Gokce 2019	21	64	6	62	-		[1.47; 7.83]	14.0%	30.9
Fixed effect model	33	176	27	179			[0.77; 1.99]	61.0%	
Random effects model	00	170	2.1	175			[0.25; 7.68]	01.070	65.0
Heterogeneity: $I^2 = 90\%$ , $\tau^2 =$	= 1.3687, j	p < 0.01					[0.00]		
Primary or post–extuba	tion res	pirator	v suppo	rt					
Hochwald 2021	16	83	17	83		0.94	[0.51; 1.73]	39.0%	35.0
Fixed effect model	16	83	17	83			[0.51; 1.73]	39.0%	
Random effects model							[0.51; 1.73]		35.0
Heterogeneity: not applicable	D								
Fixed effect model	49	259	44	262		1.12	[0.77; 1.63]	100.0%	
Random effects model						1.20	[0.48; 3.01]		100.0
Heterogeneity: $l^2 = 81\%$ , $\tau^2 =$	= 0.5365, p	p < 0.01			2 0.5 1 2 5	10			
Test for subgroup differences Test for subgroup differences	s (fixed effe	ect): $\chi_1^2$	= 0.48, df	= 1 (p =	2 0.5 1 2 5	10			
rest for subgroup differences	RAM ca			) di = i ( Others				Weight	Weig
Study			Events		IMV requirement	RR	95%-CI	-	(randor
CPAP									
Maram 2021	11	112	13	117		0.88	[0.41; 1.89]	35.5%	32.7
Fixed effect model	11	112	13	117			[0.41; 1.89]	35.5%	04
Random effects model							[0.41; 1.89]		32.7
Heterogeneity: not applicable	9						[,		
NIPPV									
Gokce 2019	21	64	6 17	62			[1.47; 7.83]	17.0%	30.8
Hochwald 2021	16 37	83	17	83			[0.51; 1.73]	47.5%	36.5
Fixed effect model	37	147	23	145			[0.99; 2.55]	64.5%	-
Random effects model						1.73	[0.49; 6.12]		67.3
Heterogeneity: $I^2 = 83\%$ , $\tau^2 =$	= 0.6946, ;	p = 0.01							
Fixed effect model	48	259	36	262	-	1.34	[0.90; 1.99]	100.0%	
Random effects model						1.37	[0.61; 3.04]		100.0
Heterogeneity: $l^2 = 72\%$ , $\tau^2 =$	= 0.3582, (	p = 0.03			2 05 1 2 5				
Test for subgroup differences Test for subgroup differences	s (fixed effe	ect): χ <sub>1</sub> <sup>2</sup>	= 1.64, df	= 1 (p =	2 0.5 1 2 5	10			
reactor adogroup dimensiones	(iailooini	enectay	λ <sub>1</sub> = 0.75	, 01 = 1 (					
	RAM ca	innula	(	Others				Weight	Weig
Study	Events	Total	Events	Total	Surfactant requirement	RR	95%-CI	(fixed)	(randor
Primary respiratory sup	oport								
Gokce 2019	27	64	12	62	11 m	2.18	[1.22; 3.91]	24.3%	44.8
Fixed effect model	27	64	12	62		2.18	[1.22; 3.91]	24.3%	
Random effects model						2.18	[1.22; 3.91]		44.8
Heterogeneity: not applicable	Ð								
		pirator	y suppo	rt					
Primary or post-extuba	tion resp	priceroi				1.03	[0.74; 1.42]	75.7%	55.2
Primary or post–extuba Hochwald 2021	ition resp 39	83	38	83			[0.74, 1.42]	1011 /0	
			<b>38</b> 38	<b>83</b> 83	-		[0.74; 1.42]	75.7%	
Hochwald 2021	39	83				1.03			55.2
Hochwald 2021 Fixed effect model	<b>39</b> 39	83				1.03	[0.74; 1.42]		55.2
Hochwald 2021 Fixed effect model Random effects model	<b>39</b> 39	83				1.03 1.03	[0.74; 1.42]	75.7%	55.2

Test for subgroup differences (fixed effect):  $\chi_1^2 = 4.87$ , df = 1 (p = 0.03) Test for subgroup differences (random effects):  $\chi_1^2 = 4.87$ , df = 1 (p = 0.03)

**Figure 2.** Forest plots depicting the effect estimates for the outcomes: treatment failure, invasive mechanical (IMV) requirement, and surfactant requirement.

**Table 2.** Certainty of evidence assessment for RAM cannula compared to other interfaces (binasal prongs and/or nasal mask) in preterm neonates requiring noninvasive respiratory support.

		Cert	ainty Assessmen	ıt					Summary of	Findings		
							Study Event Rates (%)			Anticipated Absolute Effects		
Participants (Studies) Follow-Up	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publicatio Bias	Overall Certainty of Evidence	With Other Interfaces (Binasal Prongs and/or Nasal Mask)	With RAM Cannula	Relative Effect (95% CI)	Risk with other Interfaces (Binasal Prongs and/or Nasal Mask)	Risk Difference with RAM Cannula	
						Treatmen	failure					
521 (3 RCTs)	not serious	very serious <sup>a</sup>	serious <sup>b</sup>	serious <sup>c</sup>	none	$\underset{low}{\oplus \bigcirc \bigcirc \bigcirc} \operatorname{Very}$	44/262 (16.8%)	49/259 (18.9%)	<b>RR 1.20</b> (0.48 to 3.01)	168 per 1000	34 more per 1000 (from 87 fewer to 338 more)	
					Invasi	ve mechanical ve	ntilation requirement					
521 (3 RCTs)	not serious	serious d	not serious <sup>e</sup>	serious <sup>f</sup>	none	⊕⊕⊖⊖ Low	16/262 (6.1%)	36/259 (13.9%)	RR 1.37 (0.67 to 3.04)	61 per 1000	<b>23 more per 1000</b> (from 20 fewer to 125 more)	
						Surfactant re	quirement					
292 (2 RCTs)	not serious	very serious <sup>a</sup>	serious b	serious <sup>c</sup>	none	⊕⊖⊖⊖ Very low	66/145 (45.5%)	66/147 (44.9%)	RR 1.44 (0.68 to 3.04)	455 per 1000	<b>200 more per 1000</b> (from 146 fewer to 929 more)	
						Air le	ak					
521 (3 RCTs)	not serious	not serious	serious b	serious <sup>c</sup>	none	$\oplus \oplus \bigcirc \bigcirc$ Low	6/262 (2.3%)	7/259 (2.7%)	<b>RR 1.20</b> (0.36 to 4.00)	23 per 1000	<b>5 more per 1000</b> (from 15 fewer to 69 more)	

		Cert	ainty Assessmen	t					Summary of	Findings	
							Study Event R	ates (%)			ed Absolute Effects
Participants (Studies) Follow-Up	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publicatio Bias	Overall Certainty of Evidence	With Other Interfaces (Binasal Prongs and/or Nasal Mask)	With RAM Cannula	Relative Effect (95% CI)	Risk with other Interfaces (Binasal Prongs and/or Nasal Mask)	Risk Difference with RAM Cannula
					Durat	ion of invasive me	chanical ventilation				
292 (2 RCTs)	serious g	very serious <sup>a</sup>	not serious <sup>e</sup>	serious h	none	⊕⊖⊖⊖ Very low	145	147	-		MD <b>5.07 days higher</b> (1.04 lower to 11.19 higher)
					Durati	on of non-invasiv	e respiratory support				
521 (3 RCTs)	not serious <sup>i</sup>	very serious <sup>a</sup>	not serious <sup>e</sup>	serious h	none	$\oplus \bigcirc \bigcirc \bigcirc$ Very low	262	259	-		MD 2.85 days higher (0.95 lower to 6.64 higher)
						Oropharynge	al pressure				
106 (2 ob- servational studies)	serious <sup>j</sup>	very serious <sup>a</sup>	not serious	serious <sup>f</sup>	none	⊕⊖⊖⊖ Very low	52	54	-		MD <b>1.84 cm H<sub>2</sub>O lower</b> (3.12 lower to 0.56 lower)
						Nasal Tr	auma				
521 (3 RCTs)	not serious	serious a	not serious	serious <sup>c</sup>	none	$\oplus \oplus \bigcirc \bigcirc$ Low	67/262 (25.6%)	31/259 (12.0%)	<b>RR 0.49</b> (0.21 to 1.11)	256 per 1000	<b>130 fewer per 1000</b> (from 202 fewer to 28 more)

Table 2. Cont.

**Explanations:** <sup>a</sup> 12 > 75%. <sup>b</sup> Indirectness related to patient population as Hoschwald et al. study had enrolled neonates who required noninvasive respiratory support as a primary as well as a post-extubation mode. <sup>c</sup> 95% CI crossing line of no effect and Optimal Information Criterion (OIS) not satisfied due to low sample size and low event rates. <sup>d</sup> 12 > 50%. <sup>e</sup> Although there was indirectness related to patient population in the study of Hoschwald et al. as it had enrolled neonates who required noninvasive respiratory support as a primary as well as a post-extubation mode, the weightage for this study was minimal. Hence, the certainty of evidence was not downrated for indirectness. <sup>f</sup> OIS not satisfied. <sup>g</sup> Of the two studies, the study by Gocke et al., which had the highest weightage, had some concerns. <sup>h</sup> 95% CI crossing line of no effect. <sup>i</sup> Of the three RCTs, though the study by Gocke et al. had some concerns in risk of bias overall, the weightage of this study was 35.7%. Hence, the certainty of evidence was not downrated for risk of bias. <sup>j</sup> Of the two observational studies, that of Sharma et al. had a serious risk of overall bias. Certainty of evidence levels: +very low, ++ low, +++ moderate, ++++ high.

#### Need for IMV

The meta-analysis showed that clinical benefit or harm could not be ruled out with CLNT compared with NRS provided with SBP [RR 1.37, 95% CI 0.61–3.04; risk difference 23 more per 1000, 95% CI 20–125 more; 3 studies, 521 participants]. The CoE was rated down by two levels to low due to serious limitations of inconsistency and imprecision (Figure 3, Table 2). The test for subgroup differences was not significant.

#### 3.3. Secondary Outcomes

# 3.3.1. Nasal Trauma

Clinical benefit or harm could not be ruled out for the outcome of nasal trauma between the two groups [RR 0.49, 95% CI 0.21–1.11; 3 studies, 521 participants; CoE: low]. The test for subgroup differences for NRS modes, NCPAP and NIPPV, was significant. (Figure 3, Table 2).

# 3.3.2. Surfactant Treatment

Clinical benefit or harm could not be ruled out for the outcome of surfactant therapy between the two groups [RR 1.44, 95% CI 0.68–3.04; 2 studies, 292 participants; CoE: very low] (Figure 2, Table 2). The test for subgroup differences was significant.

## 3.3.3. Duration of IMV

The meta-analysis of 2 studies involving 292 participants could not provide any meaningful interpretation with the use of CLNT when compared to other interfaces [mean difference (MD) of 5.07 days and 95% CI of -1.04 to 11.19 days]. The CoE was rated down to very low certainty due to serious limitations in the study design, serious risk of bias, high heterogeneity, and imprecision (Figure 3, Table 2). The test for subgroup differences was significantly different.

Clinical benefit or harm could not be ruled out for the outcome of duration of NRS between the two groups [MD 2.85 days, 95% CI -0.95 to 6.64; 3 studies, 521 participants], and CoE was very low (Figure 4, Table 2).

Study	Event	Total	Events	Total	Air leak	RR	95%-CI	Weight	Weig (randor
	Events	rotal	Events	Iotai	AIT leak	нR	95%-CI	(fixed)	(randor
rimary respiratory sup	port								
Aaram 2021	3	112	1	117		<ul> <li>3.13</li> </ul>	[0.33; 29.68]	16.2%	27.8
Gokce 2019	1	64	3	62 ←	- <b></b>	0.32	[0.03; 3.02]	50.6%	28.1
Fixed effect model	4	176	4	179		1.01	[0.26; 3.92]	66.8%	
Random effects model				_		1.00	[0.11; 9.30]		55.8
leterogeneity: $l^2 = 49\%$ , $\tau^2 =$	1 2720	0 - 0 16			1		[0111] 0100]		0010
leterogeneity. r = 48%, t =	- 1.2730, j	0 = 0.10							
rimary or post-extuba	tion res	piratory	/ suppor	rt					
Hochwald 2021	3	83	2	83	! <b>=</b>	1.50	[0.26; 8.75]	33.2%	44.2
Fixed effect model	3	83	2	83		1.50	[0.26; 8.75]	33.2%	
Random effects model	0				i i	1.50	[0.26; 8.75]		44.2
					5	1.50	[0.20; 0.75]		44.2
leterogeneity: not applicable	0								
Fixed effect model	7	259	6	262	6	1.17	[0.40; 3.42]	100.0%	
andom effects model			-		1		[0.36; 4.00]		100.0
						1.20	[0.30, 4.00]		100.0
deterogeneity: $l^2 = 4\%$ , $\tau^2 = 1$	0.0488, p	= 0.35		0.1	.2 0.5 1 2 5 1	10			
est for subgroup differences	(fixed effe	ect): $\chi_1^2 =$	0.12, df =	1 (p = 0.73					
est for subgroup differences	(random	effects):	$\chi_1^2 = 0.08$	df = 1 (p = 0	)				
Study	RAM ca		Events	Others	Nasal trauma	RR	95%-CI	Weight	Weig
Sludy	Events	Total	Events	Total	Nasai traunia	nn	93%-01	(lixed)	(randon
CPAP					§				
Maram 2021	6	112	31	117 ←		0.20	[0.09; 0.47]	45.6%	30.7
Fixed effect model	6	112	31	117			[0.09; 0.47]	45.6%	
	0	1112	01					40.070	30.7
Random effects model						0.20	[0.09; 0.47]		30.7
Heterogeneity: not applicable	0				1				
NIPPV									
Gokce 2019	12	64	12	62		0.97	[0.47; 1.99]	18.3%	33.3
					i <b>− −</b>				
Hochwald 2021	13		24	83			[0.30; 0.99]	36.1%	36.0
Fixed effect model	25	147	36	145			[0.43; 1.08]	54.4%	-
Random effects model						0.70	[0.40; 1.23]		69.3
Heterogeneity: $I^2 = 32\%$ , $\tau^2$	= 0.0543,	p = 0.22			6				
Fixed effect model	31	259	67	262		0.47	[0.31; 0.69]	100.0%	
	51	200	0,	202				100.0 %	
Random effects model				_		0.49	[0.21; 1.11]		100.0
Heterogeneity: $I^2 = 75\%$ , $\tau^2$	= 0.4010,	p = 0.02		0.1	0.2 0.5 1 2 5	10			
Test for subgroup differences				= 1 (p = 0.01					
					0				
Test for subgroup difference:	s (random		$\chi_1^2 = 5.82$		9			Weight	Weigt
Test for subgroup difference:	s (random	effects):	$\chi_1^2 = 5.82$	, df = 1 ( <i>p</i> = other	) IMV duration	мр	95%-C	Weight I (fixed)	
Test for subgroup difference:	s (random RAM Total Mea	effects):	χ <sup>2</sup> <sub>1</sub> = 5.82	, df = 1 ( <i>p</i> = other		MD	95%–C		
Test for subgroup difference: Study T Primary respiratory supp	RAM Fotal Mea	effects): I cannul an Si	χ <sub>1</sub> <sup>2</sup> = 5.82 a D Total	, df = 1 (p = other Mean S				I (fixed)	(randon
Test for subgroup differences Study T Primary respiratory supp Gokce 2019	RAM RAM Total Mer Fort 64 10.	effects): I cannul an Si	χ <sub>1</sub> <sup>2</sup> = 5.82 a D Total	, df = 1 ( <i>p</i> = other		8.00	[ 6.03; 9.97	I (fixed)	(randon
Fist for subgroup differences Study T Primary respiratory supp Gokoe 2019 Fixed effect model	RAM Fotal Mea	effects): I cannul an Si	χ <sub>1</sub> <sup>2</sup> = 5.82 a D Total	, df = 1 (p = other Mean S		<b>8.00</b>	[6.03; 9.97	(fixed) 77.5%	(randon
Fost for subgroup differences Study T Primary respiratory supp Gokce 2019 Fread effect model Random effects model	RAM RAM Total Mer Fort 64 10.	effects): I cannul an Si	χ <sub>1</sub> <sup>2</sup> = 5.82 a D Total	, df = 1 (p = other Mean S		8.00	[6.03; 9.97 [6.03; 9.97	(fixed) 77.5%	(randon
Fost for subgroup differences Study T Primary respiratory supp Gokce 2019 Fread effect model Random effects model	RAM RAM Total Mer Fort 64 10.	effects): I cannul an Si	χ <sub>1</sub> <sup>2</sup> = 5.82 a D Total	, df = 1 (p = other Mean S		<b>8.00</b>	[6.03; 9.97	(fixed) 77.5%	(randon
Test for subgroup differences Study T Primary respiratory supp Gokce 2019 Fixed effect model Random effects model Heterogeneity: not applicable	RAM Total Mer Fort 64 10.	effects): I cannul an Si 75 7.9	a D Total 1 62 62	, df = 1 (p = other Mean S		<b>8.00</b>	[6.03; 9.97	(fixed) 77.5%	(randon
Test for subgroup differences Study T Primary respiratory supp Gokee 2019 Fixed effect model Random effects model Heterogeneity: not applicable Primary or post-extubatil	RAM Total Mer Fort 64 10.	effects): I cannul an Si 75 7.9	a D Total 1 62 62	, df = 1 (p = other Mean S		<b>8.00</b> 8.00 8.00	[6.03; 9.97	(fixed) 77.5% 77.5%	(randon 53.2' - 53.2
Test for subgroup differences Study T Primary respiratory supp Gokoe 2019 Fixed effect model Random effects model Heterogeneity: not applicable Primary or post–extubati Hochwald et al	RAM Total Mer fort 64 10. 64 on respir	effects): I cannul an Si 75 7.9	a D Total 1 62 62	other Mean S 2.75 1.5		8.00 8.00 8.00	[6.03; 9.97] [6.03; 9.97] [6.03; 9.97]	I         (fixed)           ]         77.5%           ]         77.5%           ]         —	(randon
Test for subgroup differences Study T Primary respiratory supp Gokce 2019 Fixed effect model Random effects model Heterogeneity: not applicable Primary or post–extubati Hochwald et al Fixed effect model	RAM Fotal Med fort 64 10. 64 000 respir 83 16.	effects): I cannul an Si 75 7.9	a D Total 1 62 62	other Mean S 2.75 1.5		8.00 8.00 8.00 1.75	[6.03; 9.97] [6.03; 9.97] [6.03; 9.97] [-1.91; 5.41] [-1.91; 5.41]	<ul> <li>(fixed)</li> <li>77.5%</li> <li>77.5%</li> <li>77.5%</li> <li>22.5%</li> <li>22.5%</li> </ul>	(randon 53.2 53.2 46.8
Test for subgroup differences Study T Primary respiratory supp Gokee 2019 Fixed effect model Random effects model Heterogeneity: not applicable Primary or post-extubatil Hochwaldf et al Fixed effect model Random effects model	RAM Fotal Med fort 64 10. 64 000 respir 83 16.	effects): I cannul an Si 75 7.9	a D Total 1 62 62	other Mean S 2.75 1.5		8.00 8.00 8.00 1.75	[6.03; 9.97] [6.03; 9.97] [6.03; 9.97]	<ul> <li>(fixed)</li> <li>77.5%</li> <li>77.5%</li> <li>77.5%</li> <li>22.5%</li> <li>22.5%</li> </ul>	(randon 53.2' - 53.2
Test for subgroup differences Study T Primary respiratory supp Gokce 2019 Fixed effect model Random effects model Heterogeneity: not applicable Primary or post–extubatil Hochwald et al Fixed effect model	RAM Fotal Med fort 64 10. 64 000 respir 83 16.	effects): I cannul an Si 75 7.9	a D Total 1 62 62	other Mean S 2.75 1.5		8.00 8.00 8.00 1.75	[6.03; 9.97] [6.03; 9.97] [6.03; 9.97] [-1.91; 5.41] [-1.91; 5.41]	<ul> <li>(fixed)</li> <li>77.5%</li> <li>77.5%</li> <li>77.5%</li> <li>22.5%</li> <li>22.5%</li> </ul>	(randon 53.2 53.2 46.8
est for subgroup differences Study T Primary respiratory supp Gokce 2019 Ficked effect model Random effects model Hotowaid et al Hochwaid et al Random effects model Random effects model Random effects model Random effects model	RAM Fotal Med fort 64 10. 64 000 respir 83 16.	effects): I cannul an Si 75 7.9	a D Total 1 62 62	other Mean S 2.75 1.5		8.00 8.00 8.00 1.75 1.75	[6.03; 9.97] [6.03; 9.97] [6.03; 9.97] [-1.91; 5.41] [-1.91; 5.41]	I     (fixed)       77.5%       77.5%       22.5%       22.5%	(randon 53.2 53.2 46.8
Test for subgroup differences Study T Primary respiratory supp Gokes 2019 Fixed effect model Random effects model Heterogeneity: not applicable Primary or post-extubali Hochwalfect model Random effects model	RAM Fotal Mei Fort 64 10: 64 00: 64 83 16: 83 16:	effects) i cannul an Si 75 7.9 75 7.9	a D Total 1 62 62 Jpport 4 83 83	other Mean S 2.75 1.5		8.00 8.00 8.00 1.75 1.75 1.75	[6.03; 9.97] [6.03; 9.97] [6.03; 9.97] [6.03; 9.97] [-1.91; 5.41] [-1.91; 5.41]	I     (fixed)       ]     77.5%       ]     77.5%       ]        ]     22.5%       ]        ]     100.0%	(randon 53.2 53.2 46.8

**Figure 3.** Forest plots depicting the effect estimates for the outcomes: air leak, nasal trauma, and invasive mechanical (IMV) duration.



**Figure 4.** Forest plots depicting the effect estimates for the outcomes: noninvasive respiratory support (NRS) duration and oropharyngeal pressure transmission.

# 3.3.5. Air Leak

Clinical benefit or harm could not be ruled out for the outcome of air leak between the two groups [RR 1.20, 95% CI 0.36–4.00; 3 studies, 521 participants], and the CoE was low (Figure 3, Table 2).

3.3.6. Work of Breathing (Using Objective and Validated Scoring Technique) and Pressure Transmission (at the Level of Pharynx or Oesophagus)

None of the included RCTs evaluated this outcome.

#### 3.4. Outcomes from Non-Randomised Trials

Three observational trials (Singh 2018, Sharma 2020, and Drescher 2018) which included 138 participants satisfied the eligibility criteria for this systematic review [18,22,23].

#### 3.4.1. Primary Outcomes

# Primary Outcomes

No meta-analysis was performed, as only one study reported treatment failure between the groups. The treatment failure reported by Drescher et al. was not statistically different between the two groups [RR 2.81, 95% CI 0.84 to 9.36]

# Secondary Outcomes

Oropharyngeal pressure transmission: The oropharyngeal pressure transmission was possibly lower with CLNT when compared to other nasal interfaces [MD -1.84 cm H20, 95% CI -3.12 to -0.56; 2 studies, 106 participants; CoE: very low] (Figure 4, Table 2).

No meta-analysis was performed for other secondary outcomes, as only a single observational study reported on some of these outcomes. This study (Drescher 2018) provided data for nasal trauma, IMV duration, and NRS duration. The IMV duration was significantly higher with CLNT with a mean difference of 7.58 days and 95% CI of 0.32 to 14.84. The same study reported nasal trauma as one of the secondary outcomes, which was significantly lower with CLNT [RR of 0.16, 95%CI 0.05 to 0.49, CoE: very low]. Duration of NRS was significantly lower with CLNT with a mean difference of 8.70 days and 95% CI of -15.88 to -1.52.

## 4. Discussion

In this systematic review and meta-analysis, we evaluated the efficacy of CLNT in comparison to other routinely utilized nasal interfaces for NRS, such as SBP and NM. To the best of our knowledge, this is the only systematic review and meta-analysis highlighting the evidence from six available clinical studies, three randomized (n = 521) and three non-randomized (n = 138), evaluating the efficacy of CLNT as an interface for NRS in preterm neonates for primary respiratory support or for post-extubation. Though CLNT possibly results in lower oropharyngeal pressure transmission when compared to SBP/NM (meta-analysis of non-RCTs), clinical benefit or harm could not be ruled out for most of the outcomes evaluated, highlighting the need for future trials on this question. Our finding of lower oropharyngeal pressure transmission with CLNT is consistent with the earlier in vivo and bench studies on CLNT showing lower pressure delivery with CLNT [4,15–17,19–21,36]. The RAM cannula is quite similar to the traditional nasal prongs used to provide supplemental oxygen. Its long and narrow tubing is supposed to be more effective than traditional cannula in transmitting pressures to the nasal end, which in turn is relatively soft compared to SBPs [24–26]. Due to the very low CoE, the findings of our meta-analysis need to be validated by future studies.

Of the primary outcomes evaluated, treatment failure and need for IMV were assessed separately, as these outcomes are not mutually exclusive and neonates who meet the criteria for treatment failure may be supported with a higher mode of NRS rather than being initiated on IMV. We found no significant differences for both outcomes; however, the confidence limits included a significant benefit and harm, thereby obviating the ability to draw any meaningful conclusions. The softer nasal cannula which comes in contact with the nares is perceived to be associated with lesser nasal trauma compared to SBPs or NM [24–26]. We evaluated nasal trauma as one of the secondary outcomes, and it is usually one of the determining factors for the preferential choice of a specific NRS interface in most of the neonatal units. Although our meta-analysis indicated no difference in nasal injury with the use of CLNT cannula, clinical benefit or harm could not be ruled out due to an imprecise effect estimate and low certainty of the evidence. The betweenstudies heterogeneity in this meta-analysis for the outcomes could possibly be explained by the differences in the patient population, co-interventions, baseline event rates, and the variable assessment methods and criteria used to evaluate the outcomes [24–26]. Other factors to be considered include the nurse-to-patient ratio, the skill and training of the healthcare personnel, and intensity of monitoring, all of which are known to influence the important outcomes.

Our study has several strengths. To date, to the best of our knowledge, this is the only systematic review and meta-analysis summarizing the current evidence on a pertinent question of clinical importance related to the use of an increasingly adopted NRS interface, CLNT, in preterm neonates for primary and post-extubation support. The study followed the standard methodology per the PRISMA framework, the Cochrane group guidance for systematic reviews including a comprehensive search strategy, prospective protocol registration in PROSPERO, and explicitly defined the clinical question and synthesized the evidence using appropriate methods. Lastly, our review also examines the CoE using the GRADE working group guidelines, an essential aspect to appraise the quality and strength of evidence and thereby making an informed clinical decision.

However, we acknowledge some of the limitations of this meta-analysis. Firstly, the number of studies contributing to the systematic review and meta-analysis is limited. Secondly, despite synthesizing the evidence in a meta-analysis, the confidence in the evidence for many outcomes studied is limited due to very low to low evidence certainty. We identified a few ongoing trials (CTRI NCT03121781, NCT0216825, and CTRI/2020/03/024097) that may likely address these limitations [40–42]. We also recognize that there was a lack of homogeneity among the studies about the type of NRS used as well as its indication of use (primary support versus post-extubation), comparator interfaces, varying definitions, and assessment of primary and secondary outcomes, as evident by statistical heterogeneity for

many outcomes. We explored the heterogeneity by pooling the studies as subgroups based on the type and indication of NRS and found the test for subgroup differences was statistically significant for some outcomes suggesting one of possible reasons for the observed heterogeneity. We also attempted to study the subgroup data based on the gestational age of the included neonates: (<28 weeks versus >28 weeks). However, limited reporting in the included RCTs or observational studies precluded such analyses.

#### 5. Conclusions

The results of this meta-analysis indicate that compared to SBP or NM, the use of CLNT as an interface for NRS either as a primary support modality or for post-extubation in preterm neonates possibly results in reduced oropharyngeal pressure transmission; however, the meta-analysis could not assess with certainty the effect on important clinical outcomes. Henceforth, we suggest this as priority research and until more high-quality evidence is available, clinicians should consider proven nasal interfaces, such as NM or SBP, that are likely to provide effective pressure transmission, adequate ventilation, and oxygenation, thereby possibly avoiding IMV in preterm neonates.

**Supplementary Materials:** The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/children9101461/s1, Table S1: literature search strategy; Table S2: statements to communicate the findings of the systematic review; Table S3: excluded studies; Table S4: risk of bias for randomized controlled trials; Table S5: risk of bias for non-randomized controlled trials.

**Author Contributions:** Conceptualization, P.A. and M.K.; methodology, P.A., M.K., V.V.R., A.R. and A.K.P.S.; formal analysis, V.V.R.; data curation, A.K.P.S. and A.R.; writing—original draft preparation, P.A.; writing—review and editing, P.A., M.K., V.V.R., A.R., A.K.P.S. and D.T.; supervision, V.V.R. and D.T. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding. Abdul Razak's research is supported by Monash University, Australia.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

**Data Availability Statement:** Original data are available upon reasonable request to the corresponding author.

**Conflicts of Interest:** The authors declare no conflict of interest.

#### References

- Ramaswamy, V.V.; Bandyopadhyay, T.; Nanda, D.; Bandiya, P.; More, K.; Oommen, V.I.; Gupta, A. Efficacy of noninvasive respiratory support modes as postextubation respiratory support in preterm neonates: A systematic review and network meta-analysis. *Pediatr. Pulmonol.* 2020, 55, 2924–2939. [CrossRef] [PubMed]
- Cummings, J.J.; Polin, R.A.; Committee on Fetus and Newborn; American Academy of Pediatrics. Non-invasive respiratory support. *Pediatrics* 2016, 137, e20153758. [CrossRef] [PubMed]
- 3. Ho, J.J.; Subramaniam, P.; Davis, P.G. Continuous positive airway pressure (CPAP) for respiratory distress in preterm neonates. *Cochrane Database Syst. Rev.* **2020**, *10*, CD002271. [PubMed]
- 4. Bailes, S.A.; Firestone, K.S.; Dunn, D.K.; McNinch, N.L.; Brown, M.F.; Volsko, T.A. Evaluating the effect of flow and interface type on pressures delivered with bubble CPAP in a simulated model. *Respir. Care* **2016**, *61*, 333–339. [CrossRef]
- Bashir, T.; Murki, S.; Kiran, S.; Reddy, V.K.; Oleti, T.P. 'Nasal mask' in comparison with 'nasal prongs' or 'rotation of nasal mask with nasal prongs' reduces the incidence of nasal injury in preterm neonates supported on nasal continuous positive airway pressure (nCPAP): A randomized controlled trial. *PLoS ONE* 2019, 14, e0211476. [CrossRef]
- 6. De Bonfim, S.F.S.F.; de Vasconcelos, M.G.L.; de Sousa, N.F.C.; da Silva, D.V.C.; Leal, L.P. Nasal septum injury in preterm neonates using nasal prongs. *Rev. Lat. Am. Enfermagem.* **2014**, *22*, 826–833. [CrossRef]
- 7. Fujii, K.; Sugama, J.; Okuwa, M.; Sanada, H.; Mizokami, Y. Incidence and risk factors of pressure ulcers in seven neonatal intensive care units in Japan: A multisite prospective cohort study. *Int. Wound J.* 2010, *7*, 323–328. [CrossRef]
- 8. Ota, N.T.; Davidson, J.; Guinsburg, R. Early nasal injury resulting from the use of nasal prongs in preterm neonates with very low birth weight: A pilot study. *Rev. Bras. Ter. Intensiva* 2013, 25, 245–250. [CrossRef]

- Yong, S.C.; Chen, S.J.; Boo, N.Y. Incidence of nasal trauma associated with nasal prong versus nasal mask during continuous positive airway pressure treatment in very low birthweight neonates: A randomised control study. *Arch. Dis. Child. Fetal Neonatal Ed.* 2005, *90*, F480–F483. [CrossRef]
- 10. Ottinger, D.; Hicks, J.; Wilson, S.; Sperber, K.; Power, K. The pressure is on! Neonatal skin and nasal continuous positive airway pressure. *Adv. Neonatal Care Off. J. Natl. Assoc. Neonatal Nurses* **2016**, *16*, 420–423. [CrossRef]
- 11. Imbulana, D.I.; Manley, B.J.; Dawson, J.A.; Davis, P.G.; Owen, L.S. Nasal injury in preterm neonates receiving non-invasive respiratory support: A systematic review. *Arch. Dis. Child. Fetal Neonatal Ed.* **2018**, 103, F29–F35. [CrossRef]
- 12. Nzegwu, N.I.; Mack, T.; DellaVentura, R.; Dunphy, L.; Koval, N.; Levit, O.; Bhandari, V. Systematic use of the RAM nasal cannula in the Yale-New Haven Children's Hospital Neonatal Intensive Care Unit: A quality improvement project. *J. Matern. Fetal Neonatal Med.* **2015**, *28*, 718–721. [CrossRef]
- 13. Razak, A.; Patel, W. Nasal mask vs binasal prongs for nasal continuous positive airway pressure in preterm neonates: A systematic review and meta-analysis. *Pediatr. Pulmonol.* 2020, *55*, 2261–2271. [CrossRef] [PubMed]
- 14. Ramanathan, R. Nasal respiratory support through the nares: Its time has come. J. Perinatol. 2010, 30, S67–S72. [CrossRef]
- Claassen, C.C.; Hillman, N.H.; Brown, K.; Williams, H.L.; Strand, M.L. Comparison of bubble CPAP devices using RAM cannula for extubation failure in very low birth weight neonates: Randomized and cohort studies. *Neonatology* 2019, 115, 28–35. [CrossRef] [PubMed]
- Matlock, D.N.; Bai, S.; Weisner, M.D.; Comtois, N.; Beck, J.; Sinderby, C.; Courtney, S.E. Tidal volume transmission during non-synchronized nasal intermittent positive pressure ventilation via RAM cannula. J. Perinatol. 2019, 39, 723–729. [CrossRef]
- 17. Green, E.A.; Dawson, J.A.; Davis, P.G.; de Paoli, A.G.; Roberts, C.T. Assessment of resistance of nasal continuous positive airway pressure interfaces. *Arch. Dis. Child. Fetal Neonatal Ed.* **2019**, *104*, F535–F539. [CrossRef] [PubMed]
- Sharma, D.; Murki, S.; Maram, S.; Pratap, T.; Kiran, S.; Venkateshwarlu, V.; Dinesh, P.; Kulkarni, D.; Kamineni, B.T.A.; Singh, G. Comparison of delivered distending pressures in the oropharynx in preterm infant on bubble CPAP and on three different nasal interfaces. *Pediatr. Pulmonol.* 2020, 55, 1631–1639. [CrossRef]
- 19. Gerdes, J.S.; Sivieri, E.M.; Abbasi, S. Factors influencing delivered mean airway pressure during nasal CPAP with the RAM cannula. *Pediatr. Pulmonol.* **2016**, *51*, 60–69. [CrossRef]
- Mukerji, A.; Belik, J. Neonatal nasal intermittent positive pressure ventilation efficacy and lung pressure transmission. *J. Perinatol.* 2015, 35, 716–719. [CrossRef]
- Iyer, N.P.; Chatburn, R. Evaluation of a nasal cannula in noninvasive ventilation using a lung simulator. *Respir. Care* 2015, 60, 508–512. [CrossRef] [PubMed]
- Drescher, G.S.; Hughes, C.W. Comparison of interfaces for the delivery of noninvasive respiratory support to low birthweight neonates. *Respir. Care* 2018, 63, 1197–1206. [CrossRef] [PubMed]
- 23. Singh, N.; McNally, M.J.; Darnall, R.A. Does the RAM cannula provide continuous positive airway pressure as effectively as the Hudson prongs in preterm neonates? *Am. J. Perinatol.* **2019**, *36*, 849–854. [CrossRef] [PubMed]
- 24. Gokce, I.K.; Kaya, H.; Ozdemir, R. A randomized trial comparing the short binasal prong to the RAM cannula for noninvasive ventilation support of preterm neonates with respiratory distress syndrome. *J. Matern. Fetal Neonatal Med.* **2019**, *34*, 1868–1874. [CrossRef]
- Hochwald, O.; Riskin, A.; Borenstein-Levin, L.; Shoris, I.; Dinur, G.P.; Said, W.; Jubran, H.; Littner, Y.; Haddad, J.; Mor, M.; et al. Cannula with long and narrow tubing versus short binasal prongs for noninvasive ventilation in preterm neonates: Noninferiority randomized clinical trial. *JAMA Pediatr.* 2021, 175, 36–43. [CrossRef]
- 26. Maram, S.; Murki, S.; Nayyar, S.; Kadam, S.; Oleti, T.P.; Anne, R.P.; Deshobhotla, S.; Sharma, D.; Arun, S.; Vadije, P.R. RAM cannula with Cannulaide versus Hudson prongs for delivery of nasal continuous positive airway pressure in preterm neonates: An RCT. *Sci. Rep.* **2021**, *11*, 23527. [CrossRef]
- 27. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* 2021, *10*, 89. [CrossRef]
- R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2020. Available online: https://www.R-project.org/ (accessed on 15 August 2022).
- 29. Hozo, S.P.; Djulbegovic, B.; Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med. Res. Methodol.* **2005**, *5*, 13. [CrossRef]
- Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.; Corbett, M.S.; Eldridge, S.M.; et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ* 2019, *366*, 14898. [CrossRef]
- Sterne, J.A.; Hernán, M.A.; Reeves, B.C.; Savović, J.; Berkman, N.D.; Viswanathan, M.; Henry, D.; Altman, D.G.; Ansari, M.T.; Boutron, I.; et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016, 355, i4919. [CrossRef]
- 32. Guyatt, G.H.; Oxman, A.D.; Kunz, R.; Brozek, J.; Alonso-Coello, P.; Rind, D.; Devereaux, P.J.; Montori, V.M.; Freyschuss, B.; Vist, G.; et al. GRADE guidelines 6. Rating the quality of evidence—Imprecision. J. Clin. Epidemiol. 2011, 64, 1283–1293. [CrossRef] [PubMed]
- 33. Guyatt, G.H.; Oxman, A.D.; Kunz, R.; Woodcock, J.; Brozek, J.; Helfand, M.; Alonso-Coello, P.; Glasziou, P.; Jaeschke, R.; Akl, E.A.; et al. GRADE guidelines: 7. Rating the quality of evidence—Inconsistency. *J. Clin. Epidemiol.* **2011**, *64*, 1294–1302. [CrossRef]
- 34. Guyatt, G.H.; Oxman, A.D.; Schünemann, H.J.; Tugwell, P.; Knottnerus, A. GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology. *J. Clin. Epidemiol.* **2011**, *64*, 380–382. [CrossRef] [PubMed]

- Santesso, N.; Glenton, C.; Dahm, P.; Garner, P.; Akl, E.A.; Alper, B.; Brignardello-Petersen, R.; Carrasco-Labra, A.; de Beer, H.; Hultcrantz, M.; et al. GRADE Working Group. GRADE guidelines 26: Informative statements to communicate the findings of systematic reviews of interventions. *J. Clin. Epidemiol.* 2020, *119*, 126–135. [CrossRef] [PubMed]
- 36. Claassen, C.C.; Strand, M.L.; Williams, H.L.; Hillman, N.H. Use of the RAM Cannula with Early Bubble Continuous Positive Airway Pressure Requires Higher Pressures: Clinical and In vitro Evaluations. *Am. J. Perinatol.* **2021**, *38*, 1167–1173. [CrossRef]
- 37. Chandrasekaran, A.; Thukral, A.; Jeeva Sankar, M.; Agarwal, R.; Paul, V.K.; Deorari, A.K. Nasal masks or binasal prongs for delivering continuous positive airway pressure in preterm neonates-a randomised trial. *Eur. J. Pediatr.* **2017**, *176*, 379–386. [CrossRef]
- Luistro, C.P.R. Effectiveness of Kangaroo mother care in reducing morbidity and mortality among Preterm Neonates on RAM Cannula continuous positive airway pressure: A randomized controlled trial Pediatrics Healthcare Congress 2020, 15th International Conference on Pediatrics and Neonatal Health. *Curr Pediatr Res.* 2020, 6, 5.
- 39. Conti, G.; Spinazzola, G.; Gregoretti, C.; Ferrone, G.; Cortegiani, A.; Festa, O.; Piastra, M.; Tortorolo, T.; Costa, R. Comparative bench study evaluation of different infant interfaces for non-invasive ventilation. *BMC Pulm Med.* **2018**, *18*, 57. [CrossRef]
- Providing Nasal Continuous Positive Airway Pressure for Primary Respiratory Support in Preterm Neonates with Respiratory Distress. Available online: https://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=40220 (accessed on 21 June 2022).
- Neotech RAM Cannula Versus Conventional Binasal Prong Continuous Positive Airway Pressure (CPAP) to Treat Respiratory Distress in Low-Birth-Weight Neonates. Available online: <a href="https://clinicaltrials.gov/ct2/show/NCT02168257">https://clinicaltrials.gov/ct2/show/NCT02168257</a> (accessed on 21 June 2022).
- 42. Diaphragm Electrical Activity of Preterm Neonates on nCPAP With Binasal Prongs Versus RAM Cannula. Available online: https://Clinicaltrials.Gov/Show/NCT03121781 (accessed on 21 June 2022).